MMAI

MMAI
Clinical data
Other names	MMAI; MMAi; 5-Methoxy-6-methyl-2-aminoindan
Drug class	Selective serotonin releasing agent; Entactogen
ATC code	None;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 5-Methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine;
CAS Number	136468-19-4 ;
PubChem CID	131575;
ChemSpider	116274;
UNII	JF10U4I82P;
CompTox Dashboard (EPA)	DTXSID20927886 ;
Chemical and physical data
Formula	C11H15NO
Molar mass	177.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cc2CC(N)Cc2cc1OC;
	InChI InChI=1S/C11H15NO/c1-7-3-8-4-10(12)5-9(8)6-11(7)13-2/h3,6,10H,4-5,12H2,1-2H3; Key:JLESVLCTIOAHPT-UHFFFAOYSA-N;

5-Methoxy-6-methyl-2-aminoindane (MMAI) is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a less neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogenic effects in humans. The drug has been sold as a designer drug and research chemical online since 2010.